TD Cowen Reiterates Buy Rating on Protagonist Therapeutics (PTGX)

October 14, 2024 8:06 AM EDT Send to a Friend
TD Cowen analyst Tara Bancroft reiterated a Buy rating and $65.00 price target on Protagonist Therapeutics (NASDAQ: PTGX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login